Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 13/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4693817 | 0.83 | KDM4E (0.48) | CNR1L3MBTL1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL15051725 | 0.80 | ALDH1A1 (0.42) | CNR1ALDH1A1MAPTMAPK1HTT | |
| SCHEMBL5211789 | 0.80 | ADORA1 (0.42) | CNR1SMN1; SMN2 | |
| SCHEMBL30708991 | 0.80 | KDM4E (0.50) | CNR1L3MBTL1TDP1ALDH1A1MAPK1 | |
| SCHEMBL5213125 | 0.79 | CNR1 (0.51) | CNR1L3MBTL1TDP1ALDH1A1MAPT | |
| SCHEMBL10509221 | 0.79 | CNR1 (0.53) | CNR1TDP1ALDH1A1MAPTMAPK1 | |
| SCHEMBL29470195 | 0.79 | CKS1B (0.53) | CNR1L3MBTL1TDP1ALDH1A1MAPK1 | |
| SCHEMBL383762 | 0.79 | CKS1B (0.53) | CNR1L3MBTL1TDP1ALDH1A1MAPK1 | |
| SCHEMBL1369349 | 0.78 | MAPK14 (0.45) | L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL15106352 | 0.76 | CNR1 (0.50) | CNR1TDP1ALDH1A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326706-B2 | Pyrazine modulators of cannabinoid receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326706-B2 | Pyrazine modulators of cannabinoid receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326706-B2 | Pyrazine modulators of cannabinoid receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-7205302-B2 | Anticoagulants; antilipemic agents; cardiovascular disorders | NIPPON SHINYAKU CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| CN-1301973-C | Heterocyclic derivatives and medicines | NIPPON SHINYAKU CO LTD (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1400518-B1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | NIPPON SHINYAKU CO LTD (JP) | 2007-01-17 | — | — | EP | disclosed |
| US-20050054659-A1 | Pyrazine modulators of cannabinoid receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| CN-1516690-A | Heterocyclic derivatives and medicines | �ձ���ҩ��ʽ���� | 2004-07-28 | — | — | CN | disclosed |
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | NIPPON SHINYAKU CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1400518-A1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | Nippon Shinyaku Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| EP-0088593-B1 | 1,2,4-TRIAZINE AND PYRAZINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1987-05-27 | — | — | EP | disclosed |
| US-4585861-A | ACTIVATORS OF GAMMA-AMINOBUTYRIC ACID AND BENZODIAZEPINE BINDING | ELI LILLY AND COMPANY (US) | 1986-04-29 | — | — | US | disclosed |
| US-4513135-A | GAMMA-AMINOBUTYRIC ACID BINDING AGTIVATORS | ELI LILLY AND COMPANY (US) | 1985-04-23 | — | — | US | disclosed |
| EP-0088593-A2 | 1,2,4-Triazine and pyrazine derivatives | ELI LILLY AND COMPANY (US) | 1983-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054659-A1 | Pyrazine modulators of cannabinoid receptors | CNR1, CNR2, GPR18 | CNR1 1/4885L3MBTL1 4822/4885TDP1 4013/4885 |
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | CNR2, CNR1, GPR55 | CNR1 2/4885L3MBTL1 4881/4885TDP1 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.